Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Enthusiastic postdoc with bioinformatic or wet-lab focus, or a combination

    We are looking for an enthusiastic postdoc with bioinformatic or wet-lab focus, or a combination to join the Medical Epigenomics Lab at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna. The group of Christoph Bock combines experimental and computational methods for understanding epigenome regulation in cancer, stem cells, and immune diseases.
    (Reference Code: PD Medical Epigenomics)

    The Institute [http://www.cemm.at/]
    The CeMM Research Center for Molecular Medicine is an international and interdisciplinary research institute of the Austrian Academy of Sciences. Driven by medical needs, CeMM integrates basic research and clinical expertise to pursue innovative diagnostic and therapeutic approaches focused on cancer, inflammation and immune disorders. CeMM is located in a new tailor-made building at the center of the Vienna Medical University campus, within walking distance of Vienna’s historical city center. According to a study by “The Scientist”, CeMM is among the three best places in the world to do a postdoc (excluding US institutions),
    see: http://the-scientist.com/2012/03/29/...postdocs-2012/. Vienna is frequently ranked the world’s best city to live. It is a United Nations city with a large English-speaking community. The official language at CeMM is English, as more than 30 different nationalities are represented.

    The Lab [http://www.medical-epigenomics.org/]
    The lab combines large-scale analysis of the epigenome with stem cell biology and computational modeling, in order to better understand and treat leukemia and other diseases of the blood system. We work closely with biologists and medical researchers at the Medical University of Vienna, aiming to advance personalized medicine through epigenome sequencing and bioinformatic innovation. Specific research interests include (but are not limited to):
    • Epigenomics. The lab is part of the BLUEPRINT project aimed at establishing, analyzing and interpreting comprehensive epigenome maps of >100 cell types of the blood and immune system.
    • Bioinformatics. We develop bioinformatic methods and infrastructure for analyzing DNA methylation data in the context of epigenome-wide association studies.
    • Diagnostics. Using large-scale DNA methylation mapping, bioinformatic prioritization and functional characterization, we strive to develop clinically relevant biomarkers for informing cancer therapy.


    The Principal Investigator [http://christoph-bock.org/]
    Christoph Bock received his training in computer science and business science from the Universities of Mannheim and Heidelberg (Germany). He obtained a PhD in bioinformatics from the Max Planck Institute for Informatics, for which he was awarded an Otto Hahn Medal by the Max Planck Society. Christoph did his postdoc in epigenome research at the Broad Institute of MIT and Harvard, contributing to the Roadmap Epigenomics Project. In parallel, Christoph led a research group on computational epige-netics at the Max Planck Institute for Informatics. His recent publications include papers in Cell, Molecular Cell, Nature Biotechnol-ogy, Nature Methods, Nature Reviews Cancer, Nature Reviews Genetics, Science, Genome Research, Genome Biology, PLoS Com-putational Biology and Bioinformatics (http://scholar.google.com/citations?user=9qSsTcIAAAAJ). Christoph also co-directs the high-throughput sequencing platform at CeMM, and he is a visiting professor at the Medical University of Vienna as well as a work package leader in the European epigenome mapping project (http://blueprint-epigenome.eu/).

    The Project
    The lab is driven by the ideas of all its members. If you already have a project in mind, we would like to hear from you. If not, here are a few topics for inspiration: (i) Why is leukemia a disease of the elderly? Can we identify an “epigenetic clock” that counts down toward leukemia? What is wrong with this clock in those rare cases of childhood leukemia? (ii) Can we construct a blood cancer from scratch, by inducing only epigenetic defects? Which combination of pathways provides the minimum core of an epigenetic leukemia? (iii) How can we make epigenome data useful for personalized medicine? Every physician uses Google – can we build a “Google for the epigenome”?

    The Candidate
    We are looking for highly motivated and academically outstanding candidates who want to pursue a scientific career in the emerging field of medical epigenomics. An ideal candidate would have a background in molecular biology (or human genetics, genomics, molecular medicine, etc.) or a computational discipline (bioinformatics, physics, engineering, etc.) and a strong interest in working together with collaborators in the entire spectrum of epigenetics, medical genomics and bioinformatics.

    Applicants should submit
    Please submit cover letter, curriculum vitae, academic transcripts and contact details of three referees to [email protected]. Please indicate the reference code PD Medical Epigenomics in the subject line.

    Deadline for applications: 15 January 2013
    A more complete PDF version of this job posting is available from the following URL: http://goo.gl/DOZOJ

Latest Articles

Collapse

  • seqadmin
    Current Approaches to Protein Sequencing
    by seqadmin


    Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
    04-04-2024, 04:25 PM
  • seqadmin
    Strategies for Sequencing Challenging Samples
    by seqadmin


    Despite advancements in sequencing platforms and related sample preparation technologies, certain sample types continue to present significant challenges that can compromise sequencing results. Pedro Echave, Senior Manager of the Global Business Segment at Revvity, explained that the success of a sequencing experiment ultimately depends on the amount and integrity of the nucleic acid template (RNA or DNA) obtained from a sample. “The better the quality of the nucleic acid isolated...
    03-22-2024, 06:39 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by seqadmin, 04-11-2024, 12:08 PM
0 responses
18 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-10-2024, 10:19 PM
0 responses
22 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-10-2024, 09:21 AM
0 responses
17 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-04-2024, 09:00 AM
0 responses
48 views
0 likes
Last Post seqadmin  
Working...
X